Stockscreener 앱 받기
1.11
5.13%
-0.06
시간 외 거래:
1.12
0.01
+0.90%
Immunic Inc 주식(IMUX)의 최신 뉴스
Earnings Update: Whats the analyst consensus on Immunic IncDay Trade & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
HC Wainwright Has Bearish Estimate for Immunic Q1 Earnings - MarketBeat
Dentons Advises Immunic, Inc. on Private Placement and Royalty Transactions - Dentons
IMUX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Immunic to present at healthcare investor conferences in March - Yahoo Finance
Immunic to Participate in Investor Conferences in March - PR Newswire
Head to Head Review: Neuphoria Therapeutics and Immunic - National Today
Reverse stock split vote at Immunic (NASDAQ: IMUX) tied to Nasdaq listing - Stock Titan
Multiple Sclerosis Competitive Landscape 2026: 75+ Companies, 80+ Pipeline Therapies, 15+ Key FDA & Clinical Milestones Driving the Future of Multiple Sclerosis Treatment, analyses DelveInsight - Barchart.com
Immunic, Inc.Common Stock (NQ: IMUX - The Chronicle-Journal
H.C. Wainwright cuts Immunic stock price target on share count changes - Investing.com
HC Wainwright Issues Pessimistic Forecast for Immunic (NASDAQ:IMUX) Stock Price - MarketBeat
Aug Opening: Can Immunic Inc sustain earnings growthMarket Volume Summary & Risk Controlled Daily Trade Plans - baoquankhu1.vn
Immunic secures $400M to support late-stage MS trialsICYMI - Yahoo Finance
Immunic (NASDAQ:IMUX) Posts Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Trails Edge Capital Partners, LP Acquires Significant Stake in Immunic Inc - GuruFocus
BVF group details large Immunic (IMUX) pre-funded and common warrants - Stock Titan
IMMUNIC (IMUX) director Robert Nagel files initial insider Form 3 - Stock Titan
Immunic CEO on $400m financing, phase 3 MS plans - Proactive financial news
Immunic sets stage for phase 3 MS data readout after $400M financing - Proactive financial news
Immunic: Fourth Quarter Financial Overview - Bitget
IMMUNIC, INC. SEC 10-K Report - TradingView
Immunic: Q4 Earnings Snapshot - Barchart.com
Immunic (NASDAQ: IMUX) details 2025 loss and $200M private placement - Stock Titan
Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update - PR Newswire
Immunic, Inc. (NASDAQ:IMUX) Receives Average Rating of "Buy" from Analysts - MarketBeat
Analysts Offer Insights on Healthcare Companies: ProQR (PRQR), Immunic (IMUX) and Harmony Biosciences Holdings (HRMY) - The Globe and Mail
Commodore holds 13.35M IMUX shares, mostly warrant-based (IMUX) - Stock Titan
Trails Edge reports 11.45M-share position in Immunic (IMUX) via warrants - Stock Titan
Why did IMUX stock surge 33% pre-market today? - MSN
IMUX Stock Price, Forecast & Analysis | IMMUNIC INC (NASDAQ:IMUX) - ChartMill
What’s the beta of Immunic Inc. stock2025 Earnings Impact & Long-Term Investment Growth Plans - mfd.ru
Why Immunic Inc. stock is seen as undervaluedJuly 2025 Macro Moves & Safe Entry Trade Reports - mfd.ru
Vivo Opportunity files for Immunic (IMUX): 9.99% stakes via exercisable warrants - Stock Titan
What Does the Market Think About Immunic Inc? - Benzinga
Immunic Therapeutics - The Pharma Letter
Immunic (IMUX) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Immunic rises after $400M private placement, leadership transition - MSN
Immunic closes $200 million financing, may receive additional $200m By Investing.com - Investing.com Australia
Funding to support Immunic Phase 3 MS trials, commercialization - Multiple Sclerosis News Today
Immunic closes $200 million private placement - The Pharma Letter
Immunic closes $200 million financing, may receive additional $200m - Investing.com
Immunic closes $200M private placement to fund late-stage MS trials - Yahoo! Finance Canada
Immunic AG / US4525EP1011 - AD HOC NEWS
Immunic Announces Closing of Oversubscribed Private Placement Financing - PR Newswire
How Immunic Inc. stock reacts to global recession fearsJuly 2025 WrapUp & Reliable Intraday Trade Plans - mfd.ru
VIX Spike: Is Immunic Inc stock a good dividend stockWeekly Gains Report & Safe Entry Zone Identification - baoquankhu1.vn
Immunic, Inc. announced that it has received $200.010837 million in funding from a group of investors - marketscreener.com
Immunic (IMUX) Is Up 27.8% After Securing Oversubscribed $400M Raise For MS Push – What's Changed - simplywall.st
A Look At Immunic (IMUX) Valuation After Oversubscribed Funding And Leadership Changes - Yahoo Finance
Biogen Appoints Dr. Gabriela Freire as Board Chair While Immunic Inc. Searches for New CEO - geneonline.com
Immunic Completes $400 Million Private Placement to Support Transition to Commercial-Stage Operations - geneonline.com
Aug Movers: Is Immunic Inc undervalued by DCF analysisJuly 2025 Analyst Calls & Precise Buy Zone Identification - baoquankhu1.vn
Immunic MS trial shows reduced brain lesionsICYMI - Proactive financial news
Why Immunic (IMUX) Is Up 47.2% After $400 Million MS Push And Leadership Shake-Up - Yahoo Finance
3.69%
0.68%
자본화:
|
볼륨(24시간):